Endovascular Today - Latest News http://evtoday.com/ The latest news stories from Endovascular Today. en-us Sun, 20 May 2018 19:44:18 GMT Sun, 20 May 2018 19:44:18 GMT BMCToday Study Evaluates TEVAR for Chronic Type B Aortic Dissections http://evtoday.com/2018/05/16/study-evaluates-tevar-for-chronic-type-b-aortic-dissections May 15, 2018 -- A study of the outcomes of thoracic endovascular aortic repair (TEVAR) for chronic type B aortic dissection (TBAD) was published by Allan M. Conway, MBChB, et al in the Journal of Vascular Surgery (2018;67:1345 -- 1352). The investigators assessed the effectiveness of TEVAR in the treatment of chronic TBAD u... Wed, 16 May 2018 04:00:00 GMT http://evtoday.com/2018/05/16/study-evaluates-tevar-for-chronic-type-b-aortic-dissections FDA Advisory Panel Will Consider Cordis Incraft AAA Stent Graft http://evtoday.com/2018/05/16/fda-advisory-panel-will-consider-cordis-incraft-aaa-stent-graft May 16, 2018 -- The US Food and Drug Administration's (FDA's) announcement of the public advisory committee meeting of the Circulatory System Devices Panel of the forthcoming Medical Devices Advisory Committee was published in the Federal Register on May 11. The meeting will be open to the public and will be held on... Wed, 16 May 2018 04:00:00 GMT http://evtoday.com/2018/05/16/fda-advisory-panel-will-consider-cordis-incraft-aaa-stent-graft FDA Approves Portola Pharmaceuticals’ Andexxa for the Reversal of Factor Xa http://evtoday.com/2018/05/16/fda-approves-portola-pharmaceuticals-andexxa-for-the-reversal-of-factor-xa May 14, 2018 -- Portola Pharmaceuticals, Inc. recently announced that the US Food and Drug Administration (FDA) has approved the company's Andexxa (coagulation factor Xa [recombinant], inactivated-zhzo), an antidote indicated for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed d... Wed, 16 May 2018 04:00:00 GMT http://evtoday.com/2018/05/16/fda-approves-portola-pharmaceuticals-andexxa-for-the-reversal-of-factor-xa Two-Year Data Published From Swedish Study of Primary Stenting of the SFA in Intermittent Claudication http://evtoday.com/2018/05/16/two-year-data-published-from-swedish-study-of-primary-stenting-of-the-sfa-in-intermittent-claudication May 16, 2018 -- Primary stenting of the superficial femoral artery (SFA) in patients with intermittent claudication demonstrated durable effects on health-related quality of life (HRQOL) at 24 months in a Swedish randomized controlled trial. The findings were published by Hans I. V. Lindgren, MD, et al in CardioVascular and... Wed, 16 May 2018 04:00:00 GMT http://evtoday.com/2018/05/16/two-year-data-published-from-swedish-study-of-primary-stenting-of-the-sfa-in-intermittent-claudication iSchemaView's Rapid ASPECTS Launched in Europe http://evtoday.com/2018/05/15/ischemaviews-rapid-aspects-launched-in-europe May 15, 2018 -- iSchemaView, Inc., which is focused on automated cerebrovascular imaging analysis, announced the launch of the company's Rapid ASPECTS, a digital imaging solution that assists clinicians in assessing early signs of brain ischemia in stroke. It has received European CE Mark approval. The company is introd... Tue, 15 May 2018 04:00:00 GMT http://evtoday.com/2018/05/15/ischemaviews-rapid-aspects-launched-in-europe Surmodics Acquires Embolitech's Thrombectomy Technology Assets http://evtoday.com/2018/05/14/surmodics-acquires-embolitechs-thrombectomy-technology-assets May 14, 2018 -- Surmodics, Inc. announced that it has reached an agreement to acquire Embolitech's thrombectomy platform technology and related intellectual property, which have broad potential peripheral vascular applications. Under the agreement, Surmodics will pay $5 million up front and additional amounts related to... Mon, 14 May 2018 04:00:00 GMT http://evtoday.com/2018/05/14/surmodics-acquires-embolitechs-thrombectomy-technology-assets Financing Supports Development of Vesper Medical's Venous Stents http://evtoday.com/2018/05/11/financing-supports-development-of-vesper-medicals-venous-stents May 11, 2018 -- Vesper Medical, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, announced that it has completed its Series A financing totaling $10.5 million. Vesper Medical plans to use the proceeds from this financing to complete the development of its Vesper Duo venous stent sy... Fri, 11 May 2018 04:00:00 GMT http://evtoday.com/2018/05/11/financing-supports-development-of-vesper-medicals-venous-stents International Pelvic Venous Work Group Formed in SIR/ACP Collaboration http://evtoday.com/2018/05/10/international-pelvic-venous-work-group-formed-in-sir-acp-collaboration May 10, 2018 -- Over the last several years, we have seen an increased awareness of the morbidity associated with pelvic venous disorders. The clinical spectrum of pelvic venous disorders includes chronic pelvic pain; vulvar and lower extremity varicose veins; pain in the perineum or a scrotal varicocele; lower extremity pa... Thu, 10 May 2018 04:00:00 GMT http://evtoday.com/2018/05/10/international-pelvic-venous-work-group-formed-in-sir-acp-collaboration Q3 Medical Devices Continues Expansion in China http://evtoday.com/2018/05/10/q3-medical-devices-continues-expansion-in-china May 9, 2018 -- Q3 Medical Devices Ltd. and the Boill Holding Group announced the development of a manufacturing facility in the Baoshan region of China that will open in the first half of 2019. Q3 has four wholly owned subsidiaries: one based in the United States (QualiMed, USA), two in Germany (QualiMed and AMG Internat... Thu, 10 May 2018 04:00:00 GMT http://evtoday.com/2018/05/10/q3-medical-devices-continues-expansion-in-china Expanded Indication Approved in Europe for Stryker's Trevo Retriever to Treat Stroke Up to 24 Hours After Symptom Onset http://evtoday.com/2018/05/09/expanded-indication-approved-in-europe-for-strykers-trevo-retriever-to-treat-stroke-up-to-24-hours-after-symptom-onset May 9, 2018 -- Stryker announced that the company's Trevo Retriever has received European CE Mark approval as a front-line treatment for patients experiencing acute ischemic stroke up to 24 hours from symptom onset, increasing the treatment window by 18 hours. In the company's press release, Professor Urs Fischer... Wed, 9 May 2018 04:00:00 GMT http://evtoday.com/2018/05/09/expanded-indication-approved-in-europe-for-strykers-trevo-retriever-to-treat-stroke-up-to-24-hours-after-symptom-onset Adept Medical Launches the ArmSure http://evtoday.com/2018/05/09/adept-medical-launches-the-armsure May 9, 2018 -- Adept Medical, a New Zealand-based company announced the launch of the company's ArmSure system. The device immobilizes a restless patient’s arms during procedures performed under conscious sedation to ensure the sterile field is not compromised by the patient’s hand during femoral access proc... Wed, 9 May 2018 04:00:00 GMT http://evtoday.com/2018/05/09/adept-medical-launches-the-armsure RANGER-SFA 12-Month Data Published for Boston Scientific's Ranger DCB http://evtoday.com/2018/05/09/ranger-sfa-12-month-data-published-for-boston-scientifics-ranger-dcb May 9, 2018 -- Sabine Steiner, MD, et al published 12-month results from the first-in-human RANGER-SFA trial of the Ranger paclitaxel-coated balloon (Boston Scientific Corporation) for the treatment of femoropopliteal arteries compared with uncoated balloon angioplasty. The study is available online in Journal of the Americ... Wed, 9 May 2018 04:00:00 GMT http://evtoday.com/2018/05/09/ranger-sfa-12-month-data-published-for-boston-scientifics-ranger-dcb Laerdal Medical Launches SimMan Vascular Simulation Training System http://evtoday.com/2018/05/09/laerdal-medical-launches-simman-vascular-simulation-training-system May 9, 2018 -- Laerdal Medical, in partnership with Mentice, has developed the SimMan Vascular simulation training solution for diagnostic and therapeutic endovascular procedures. The company introduced SimMan Vascular at the Simulation User Network Conference held April 30 to May 2 in Schaumburg, Illinois. SimMan Vascul... Wed, 9 May 2018 04:00:00 GMT http://evtoday.com/2018/05/09/laerdal-medical-launches-simman-vascular-simulation-training-system iSchemaView's Rapid CTA Receives FDA Clearance http://evtoday.com/2018/05/09/ischemaviews-rapid-cta-receives-fda-clearance May 9, 2018 -- iSchemaView, Inc. recently announced that it has received final clearance from the US Food and Drug Administration for the company’s Rapid CTA, which is a three-dimensional (3D) imaging solution for CTA. Rapid CTA is designed to provide physicians with fast, fully automated, and easy-to-interpret imagin... Wed, 9 May 2018 04:00:00 GMT http://evtoday.com/2018/05/09/ischemaviews-rapid-cta-receives-fda-clearance FDA Clears Scientia Vascular's Aristotle 14 Guidewire for Stroke Treatment http://evtoday.com/2018/05/09/fda-clears-scientia-vasculars-aristotle-14-guidewire-for-stroke-treatment May 9, 2018 -- Scientia Vascular LLC announced that it has received US Food and Drug Administration (FDA) clearance for its Aristotle 14 guidewire, which is used during ischemic and hemorrhagic strokes and other challenging interventional procedures. The device was cleared in January and is commercially available. Accord... Wed, 9 May 2018 04:00:00 GMT http://evtoday.com/2018/05/09/fda-clears-scientia-vasculars-aristotle-14-guidewire-for-stroke-treatment Lombard Medical Operations Acquired by MicroPort in Restructuring Transaction http://evtoday.com/2018/05/09/lombard-medical-operations-acquired-by-microport-in-restructuring-transaction May 9, 2018 -- Lombard Medical, Inc., a developer, manufacturer, and marketer of endovascular aortic aneurysm repair (EVAR) products, recently announced that MicroPort Scientific Corporation through its subsidiary, Endovascular Technology Corporation, has acquired the shares in Lombard's subsidiaries, Lombard Medical Li... Wed, 9 May 2018 04:00:00 GMT http://evtoday.com/2018/05/09/lombard-medical-operations-acquired-by-microport-in-restructuring-transaction FDA Issues Recommendations on Neurovascular Stents Used for Stent-Assisted Coiling of Unruptured Brain Aneurysms http://evtoday.com/2018/05/08/fda-issues-recommendations-on-neurovascular-stents-used-for-stent-assisted-coiling-of-unruptured-brain-aneurysms May 8, 2018 -- The US Food and Drug Administration (FDA) has issued a letter to health care providers providing recommendations on patient selection and device use of neurovascular stents for stent-assisted coiling (SAC) of brain aneurysms. The recommendations are intended to promote the safe and effective use of the device... Tue, 8 May 2018 04:00:00 GMT http://evtoday.com/2018/05/08/fda-issues-recommendations-on-neurovascular-stents-used-for-stent-assisted-coiling-of-unruptured-brain-aneurysms Intact Vascular's TOBA III Trial Completes Enrollment in Europe http://evtoday.com/2018/05/03/intact-vasculars-toba-iii-trial-completes-enrollment-in-europe May 3, 2018 -- Intact Vascular, Inc. announced that its Tack Optimized Balloon Angioplasty III (TOBA III) clinical trial has completed enrollment. A total of 200 patients have been enrolled in TOBA III at 14 sites in Europe. The prospective, multicenter, single-arm TOBA III study is designed to investigate the safety and... Thu, 3 May 2018 04:00:00 GMT http://evtoday.com/2018/05/03/intact-vasculars-toba-iii-trial-completes-enrollment-in-europe UK NICE Guidance Updated to Support Use of Prostate Artery Embolization http://evtoday.com/2018/05/02/uk-nice-guidance-updated-to-support-use-of-prostate-artery-embolization May 1, 2018 -- The United Kingdom's National Institute for Health and Care Excellence (NICE) announced the update of its guidance to allow the use of prostate artery embolization (PAE) as a treatment of benign prostatic hyperplasia. According to NICE, it first reviewed PAE treatment in 2013 but decided that more rese... Wed, 2 May 2018 04:00:00 GMT http://evtoday.com/2018/05/02/uk-nice-guidance-updated-to-support-use-of-prostate-artery-embolization EffPac Trial Evaluates iVascular's Luminor DCB at 12 Months http://evtoday.com/2018/05/01/effpac-trial-evaluates-ivasculars-luminor-dcb-at-12-months May 1, 2018 -- iVascular recently announced that 12-month results from the full clinical cohort of the EffPac randomized controlled trial studying the company's Luminor drug-coated balloon (DCB) were presented at the Charing Cross International Symposium, held April 24 -- 27 in London, United Kingdom. The main objective... Tue, 1 May 2018 04:00:00 GMT http://evtoday.com/2018/05/01/effpac-trial-evaluates-ivasculars-luminor-dcb-at-12-months